With GIP, obesity research is at odds
A radioactive prostate cancer therapy is a last lifeline for patients. Novartis can't make enough of it
As Vertex’s pivotal pain readout looms, non-opioid drug development faces a reckoning
Why do newborn screening tests vary so much from state to state?
